Revance To Present Results From Phase 3 Trial Of DaxibotulinumtoxinA On Cervical Dystonia

(RTTNews) - Revance Therapeutics Inc. (RVNC) said Thursday that it will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy, duration of effect and safety of DaxibotulinumtoxinA for Injection, for the treatment of cervical dystonia in adults, showing a meaningful reduction in signs and symptoms associated with cervical dystonia.

The company will present an ePoster with a video poster presentation at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021 taking place from September 17-22, 2021.

The company said it looks forward to filing a Supplemental Biologics License Application, which may bring us one step closer to helping patients with this debilitating condition achieve long-lasting symptom relief.

cervical dystonia is a painful and disabling chronic condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck.